Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Yanping Chen, Yan Zhang, Qianqian Chen
This paper comprehensively analyzes the caregiver burden and its influencing factors on primary caregivers in autologous hematopoietic stem cell transplantation (Auto-HSCT) with bendamustine preconditioning. Auto-HSCT refers to the transplantation of cells back to the patient, aiming to eliminate tumor cells and prolong the patient's life. Bendamustine, while enhancing the success rate of transplantation, has drawn considerable attention to the primary caregivers of patients. Due to the complex nature of the transplantation process, patients have diverse caregiving needs, which caregivers must address to support the entire treatment journey...
April 5, 2024: Alternative Therapies in Health and Medicine
#2
JOURNAL ARTICLE
Jinjing Zhang, Rui Zhang
INTRODUCTION: Megalosplenia in newly diagnosed multiple myeloma (MM) is extremely rare, posing diagnostic and therapeutic challenges due to its unusual location and clinical manifestations and lack of optimal therapeutic strategies. CASE PRESENTATION: A 65-year-old female who was previously healthy presented with a history of ecchymosis on her right leg accompanied by progressive fatigue for 2 weeks. She was admitted to our center in July 2019 due to thrombocytopenia...
April 5, 2024: Medicine (Baltimore)
#3
JOURNAL ARTICLE
Nurdan Tacyildiz, Hatice M Cakmak, Emel Unal, Handan Dincaslan, Gulsah Tanyıldız, Sonay I Özdemir, Ömer Kartal, Yasin Yılmaz, Gulsan Yavuz, Işınsu Kuzu
BACKGROUND: Long-term survivors of Hodgkin lymphoma (HL) are at risk of developing a range of late effects, with a second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The present study aims to evaluate the late side effects in children with HL. MATERIALS AND METHODS: Out of 53 HL patients, we assessed the long-term effects of childhood HL survivors (HLSs; n = 50) diagnosed between 1998 and 2019. Patient data related to chronic health conditions, and sociodemographic characteristics were compared with their siblings (n = 56)...
January 9, 2024: Indian Journal of Cancer
#4
JOURNAL ARTICLE
Kacper Kościelny, Damian Mikulski, Mateusz Nowicki, Krystyna Wyka, Małgorzata Misiewicz, Ewelina Perdas, Agnieszka Wierzbowska, Wojciech Fendler
Infectious complications of autologous hematopoietic stem cell transplantation (AHSCT) are the most common adverse effects of the therapy, resulting in prolonged hospitalization and deterioration of patient well-being. Identifying predictors of these complications is essential for improving patient outcomes and guiding clinical management. This study aimed to examine thrombospondin-1 (THBS-1) serum levels as a potential biomarker for predicting bacteremia in AHSCT recipients. Blood samples were collected from 30 patients undergoing BeEAM/BEAM (bendamustine/carmustine, etoposide, cytarabine, melphalan) conditioning regimen at subsequent time points during AHSCT...
December 19, 2023: Transplant Infectious Disease: An Official Journal of the Transplantation Society
#5
REVIEW
Gunjan Shah, Sergio Giralt, Parastoo Dahi
Melphalan, has been a major component of myeloma therapy since the 1950s. In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen used due to its potent anti-myeloma effects and manageable toxicities. Common toxicities associated with HDM include myelosuppression, gastrointestinal issues, and mucositis. Established approaches to reduce these toxicities encompass dose modification, nausea prophylaxis with 5HT3 receptor antagonists, cryotherapy, amifostine use, and growth factors...
March 2024: Blood Reviews
#6
JOURNAL ARTICLE
Felix Keil, Antonia M S Müller, Andrea Berghold, Regina Riedl, Veronika Buxhofer-Ausch, Judith Schuster, Corinne Vorburger, Alexandra Böhm, Michael Panny, Thomas Nösslinger, Richard Greil, Panagiotis Samaras, Celine Bencker, Markus Rütti, Thomas Pabst
BACKGROUND: Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide, cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell transplantation (ASCT) is feasible in lymphoma. However, randomised trials are lacking. Here, we present the first trial addressing this topic. METHODS: This multicentre, randomised, phase 2 study (BEB-trial) conducted at four haematological centres in Austria and Switzerland compares BEAM with BendaEAM in patients with relapsed lymphoma...
December 2023: EClinicalMedicine
#7
JOURNAL ARTICLE
Mani Ramzi, Elaheh Vafaie, Hourvash Haghighinejad, Hashim Imran
Background: High-dose chemotherapy followed by Autologous SCT (stem cell transplantation) is a treatment of choice for relapsed and refractory lymphoma. Due to cost, toxicity, and shortage of Carmustine, we decided to conduct a phase 2 clinical trial to evaluate the safety and efficacy of Bendamustine instead of Carmustine in a previously used BEAM-like protocol. Materials and Methods :102 patients (median age,37) with Hodgkin(n=54) and non-Hodgkin lymphoma(n=48) were recruited and transplanted in two centers...
April 1, 2023: International Journal of Hematology-oncology and Stem Cell Research
#8
JOURNAL ARTICLE
Yuan Fu, You-Fan Feng, Fei Liu, Qiao-Lin Chen, Wen-Jie Zhang, Qing-Fen Li, Xiao-Fang Wei, Qi-Ke Zhang
OBJECTIVE: To investigate the clinical efficacy and safety of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma. METHODS: The clinical data of 35 patients with lymphoma, including 5 patients of Hodgkin lymphoma and 30 patients of non-Hodgkin lymphoma, who underwent autologous stem cell transplantation after pretreatment with BeEAM regimen from January 2020 to June 2022 in Gansu Provincial Hospital were retrospectively analyzed...
2023: Zhongguo Shi Yan Xue Ye Xue za Zhi
#9
Luca Tomisti, Francesca Angelotti, Mirco Lenzi, Francesco Amadori, Giovanni Sarteschi, Anna Porcu, Anna-Lisa Capria, Gloria Bertacca, Stefania Lombardi, Guido Bianchini, Antonella Vincenti, Novella Cesta
The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical trials on CP have shown contradictory results, but an increasing number of patients, including immunocompromised ones, have shown benefits from this treatment. We reported two clinical cases of patients with prolonged COVID-19 infection and B-cell depletion who showed rapid clinical and virological recovery after the administration of CP...
May 27, 2023: Life
#10
JOURNAL ARTICLE
Ran Wu, Liyuan Ma
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL), and it is also used as first-line clinical consolidation option for some aggressive NHL subtypes. Conditioning regimen prior to ASCT is one of the essential factors related with clinical outcomes post transplant. The conditioning regimen of carmustine, etoposide, cytarabine, and melphalan (BEAM) traditionally is considered the standard of care for patients with lymphoma who are eligible for transplantation...
2023: Cell Transplantation
#11
REVIEW
Bruno Almeida Costa, Tarek H Mouhieddine, Ricardo J Ortiz, Joshua Richter
From the 1960s to the early 2000s, alkylating agents (e.g., melphalan, cyclophosphamide, and bendamustine) remained a key component of standard therapy for newly-diagnosed or relapsed/refractory multiple myeloma (MM). Later on, their associated toxicities (including second primary malignancies) and the unprecedented efficacy of novel therapies have led clinicians to increasingly consider alkylator-free approaches. Meanwhile, new alkylating agents (e.g., melflufen) and new applications of old alkylators (e.g...
July 2023: Critical Reviews in Oncology/hematology
#12
JOURNAL ARTICLE
Thanawat Rattanathammethee, Lalita Norasetthada, Udomsak Bunworasate, Kitsada Wudhikarn, Jakrawadee Julamanee, Panarat Noiperm, Theerin Lanamtieng, Pisa Phiphitaporn, Manassamon Navinpipat, Piyapong Kanya, Dusit Jit-Ueakul, Somchai Wongkhantee, Thanongsak Suwannathen, Juthatip Chaloemwong, Peerapon Wong, Nisa Makruasi, Archrob Khuhapinant, Kannadit Prayongratana, Pimjai Niparuck, Nonglak Kanitsap, Tawatchai Suwanban, Tanin Intragumtornchai
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand...
May 18, 2023: Annals of Hematology
#13
RANDOMIZED CONTROLLED TRIAL
Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B L Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
BACKGROUND: Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. METHODS: In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) or 12 cycles of venetoclax-rituximab, venetoclax-obinutuzumab, or venetoclax-obinutuzumab-ibrutinib...
May 11, 2023: New England Journal of Medicine
#14
JOURNAL ARTICLE
Marie-Élaine Plante, Xue Feng, Jean-Samuel Boudreault
One of the most widely accepted conditioning regimens for hematopoietic stem cell transplantation (HSCT) is BEAM (carmustine, etoposide, cytarabine, melphalan). However, a recent increase in the cost of carmustine has limited its use bringing our institution to replace carmustine with bendamustine. This observational retrospective single-center study aims to report the efficacy and safety of the BeEAM regimen. 55 patients with diffuse large B-cell lymphoma (47%), Hodgkin lymphoma (25%), mantle cell lymphoma (25%), or follicular lymphoma (2%) were included...
May 8, 2023: Leukemia & Lymphoma
#15
JOURNAL ARTICLE
Alexander D Heini, Philipp Beck, Ulrike Bacher, Katja Seipel, Thilo Zander, Michael Daskalakis, Thomas Pabst
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom's macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives. In this pilot study, we investigated high-dose chemotherapy with BeEAM, in which BCNU is replaced with high-dose bendamustine as an alternative conditioning regimen in six subsequent patients with WM...
March 19, 2023: Journal of Clinical Medicine
#16
JOURNAL ARTICLE
Fei Xue, Peihao Zheng, Rui Liu, Shaomei Feng, Yuelu Guo, Hui Shi, Haidi Liu, Biping Deng, Teng Xu, Xiaoyan Ke, Kai Hu
OBJECTIVE: The objective is to explore the effectiveness and safety of CAR T-cell therapy in advanced relapsed/refractory central nervous system B-cell lymphoma and compare the impact of autologous stem cell transplantation (ASCT) plus CAR T-cell therapy versus sequential CART therapy on the survival of patients. METHODS: The retrospective analysis was based on the data of 17 patients with advanced relapsed/refractory central nervous system B-cell lymphoma. Bridging chemotherapy was applied before CAR T-cell infusion to further reduce the tumor burden...
2022: Journal of Oncology
#17
JOURNAL ARTICLE
James C Pino, Alexander L R Lubbock, Leonard A Harris, Danielle B Gutierrez, Melissa A Farrow, Nicole Muszynski, Tina Tsui, Stacy D Sherrod, Jeremy L Norris, John A McLean, Richard M Caprioli, John P Wikswo, Carlos F Lopez
Technological advances have made it feasible to collect multi-condition multi-omic time courses of cellular response to perturbation, but the complexity of these datasets impedes discovery due to challenges in data management, analysis, visualization, and interpretation. Here, we report a whole-cell mechanistic analysis of HL-60 cellular response to bendamustine. We integrate both enrichment and network analysis to show the progression of DNA damage and programmed cell death over time in molecular, pathway, and process-level detail using an interactive analysis framework for multi-omics data...
November 18, 2022: IScience
#18
JOURNAL ARTICLE
Sylvie Lachance, Alex Bourguignon, Josie-Anne Boisjoly, Philippe Bouchard, Imran Ahmad, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Isabelle Fleury, Thomas Kiss, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux, Justine Zehr, Miguel Chagnon, Jean Roy
With the advent of new cellular and targeted therapies, treatment options for relapsed and refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best outcomes remains a matter of passionate debate. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is still considered a treatment option for patients with chemosensitive lymphoma when cure is the expected goal. The myeloablative conditioning regimen preceding the stem cell infusion is considered the effective component of this approach...
January 2023: Transplantation and cellular therapy
#19
JOURNAL ARTICLE
Shaimaa El-Ashwah, Noreen Elbayoumi, May Denewer, Mohamed ELboghdady, Emad Azmy, Mohamed Mabed, Gehad Saleh, M A ElBaiomy, Maha Elzaafarany, Mohamed A Ebrahim, Manal A Salah-Eldin, Tawfik ElKhodary, Hayam Ghazy, Sameh Shamaa
CONTEXT: Autologous hematopoietic stem cell transplantation (ASCT) is considered the standard of care in relapsed/refractory lymphoid malignancies. One major complication is the occurrence of infection, which is directly related to high doses of chemotherapy and the consequent major immunosuppression, breach of the mucous membrane barrier in the gastrointestinal tract, and line-related infections. The most common infection in post-transplant is bacterial, fungal or viral in nature. OBJECTIVE: A case of bilharzial colitis post-ASCT for R/R diffuse large B cell lymphoma (DLBCL)...
October 2022: Clinical Lymphoma, Myeloma & Leukemia
#20
JOURNAL ARTICLE
Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke, Franz Albert Hoffmann, Cornelia Becker, Leanthe Braunert, Thomas Edelmann, Inessa Paulenz, Marcus Hitzschke, Franziska Flade, Andreas Schwarzer, Klaus Fenchel, Georg-Nikolaus Franke, Vladan Vucinic, Madlen Jentzsch, Sebastian Schwind, Saskia Hell, Donata Backhaus, Thoralf Lange, Dietger Niederwieser, Markus Scholz, Uwe Platzbecker, Wolfram Pönisch
INTRODUCTION: Autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, due to restrictive exclusion criteria, more than half of eligible patients are usually excluded from transplant studies. METHODS: This retrospective monocentric analysis included 540 patients with MM who received an ASCT between 1996 and 2019. RESULTS: Up to 2005, induction therapy consisted mainly of conventional chemotherapies, e...
August 20, 2022: Journal of Cancer Research and Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
